Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing changes in their interests in the company's Ordinary shares and American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director share allocations rather than a financial performance report.
Material Changes
On December 30, 2011, Non-Executive Directors were provisionally allocated awards under share allocation arrangements for the service period of October 1, 2011, to December 30, 2011. The allocation price was set at £14.70 per Ordinary share and $45.53 per ADS. The Company and the Non-Executive Directors were informed of these allocations on January 3, 2012.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to Disclosure and Transparency Rule 3.1.4R(1)(a) regarding director transactions.
Important Facts for Investors
- Transaction Type: Provisional allocation of share awards to Non-Executive Directors.
- Allocation Date: December 30, 2011 (Notification date: January 3, 2012).
- Share Price Basis: £14.70 per Ordinary share; $45.53 per ADS.
- Participants: Includes Sir Christopher Gent, Prof. Sir Roy Anderson, Dr Stephanie Burns, Ms Stacey Cartwright, Mr Lawrence Culp, Sir Crispin Davis, Ms Judy Lewent, Sir Deryck Maughan, Mr James Murdoch, Dr Daniel Podolsky, Mr Tom de Swaan, and Sir Robert Wilson.
- Financial Data: No operational or financial performance metrics are included in this specific filing.